Clinical trial of piperazine ferulate dispersed tablets joint clopidogrel in the treatment of coronary heart disease
10.13699/j.cnki.1001-6821.2018.05.004
- VernacularTitle:阿魏酸哌嗪分散片联合氯吡格雷治疗冠心病的临床研究
- Author:
Shi-Qin XU
1
;
Wei-Dong JIN
;
An-Kui JIA
Author Information
1. 新乡市中心医院检验科
- Keywords:
coronary heart disease;
piperazine ferulate dispersed tablets;
clopidogrel;
serum factor
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(5):501-503
- CountryChina
- Language:Chinese
-
Abstract:
Objective To research the effect of piperazine ferulate dispersed tablets joint clopidogrel in the treatment of coronary heart disease.Methods Patients with coronary heart disease was from January 2015 to December 2016 as the study subjects,according to random number table method they were divided into control group and treatment group,44cases in each group.Control group was treated with clopidogrel,preoperative acceptance of 75 mg clopidogrel,qd,and continuous treatment for 6 months.Treatment group was treated with piperazine ferulate dispersed tablets based on the control group,oral 100 mg of piperazine ferulate dispersed tablets,tid,continuous treatment for 1 month.Clinical effects,serum homocysteine (HCY),hypersensitive C-reactive protein (HsCRP),myeloperoxidase (MPO),ischemia modified albumin (IMA),and adverse drugs reactions(ADR) between two group was compared.Results Total effective rate of the treatment group and control group respectively were 90.90％ (40 cases/44 cases) and 72.72％ (32 cases/44 cases),the difference between groups was significant (P ＜ 0.05).After treatment,the serum HCY in treatment group and control group respectively were (12.48 ± 1.91) and (16.36 ±2.02) μmol · L-1;HsCRP in the two groups respectively were (1.34 ±0.17) and (3.82 ±0.56)mg · L-1,MPO in the two groups respectively were (17.36 ±2.88) and (23.26 ±4.26)mmol · L-1,IMA in the two groups respectively were (20.10 ± 2.44) and (24.91 ± 3.53) μg · L-1,the difference of above factors between groups was significantly (all P ＜ 0.05).Incidence of ADR in treatment group and control group respectively were 25.00％ (11 cases/44 cases) and 20.45％ (9 cases/44 cases),there was no significant difference (P ＞0.05).Conclusion Effect of piperazine ferulate dispersed tablets joint clopidogrel in the treatment of coronary heart disease is better than clopidogrel alone,which reduced serum HCY,HsCRP,MPO and IMA and slowed down the disease.
